Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human, Double-Blind, Placebo-Controlled, Randomized Evaluation of Single Ascending Doses of ATI-1013, a Human Monoclonal Antibody to Nicotine in Healthy Smokers

NCT07215923 is registered in ClinicalTrials.gov with Antidote Therapeutics, Inc as lead sponsor.

NCT NCT07215923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07215923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human, Double-Blind, Placebo-Controlled, Randomized Evaluation of Single Ascending Doses of ATI-1013, a Human Monoclonal Antibody to Nicotine in Healthy Smokers
Lead sponsor
Antidote Therapeutics, Inc
Phase
Phase 1
Overall status
Recruiting
Start date
October 31, 2025
Completion date
September 30, 2026
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thromboangiitis obliterans (buerger's disease)